Paper338162
The immunosuppressive effect of type II mouse interferon preparations on antibody production.
Sonnenfeld G and 2 others. Cell Immunol, 1977. Cited by 171 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The immunosuppressive effect of type II mouse interferon preparations on antibody production. Papers, record 338162. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/338162
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibody Formation | Major topic |
| Immunosuppressive Agents | Major topic |
| Interferons | Major topic |
| Ammonium Sulfate | |
| Antibody-Producing Cells | |
| BCG Vaccine | |
| Chromatography | |
| Electrophoresis, Polyacrylamide Gel | |
| Hemolytic Plaque Technique | |
| Lymphokines | |
| Tuberculin Test |
Source PubMed
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 171 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7,022,716 | The nature of the hepatitis B virus and its mode of replication. | Springer Semin Immunopathol | 1981 | https://conductscience.org/library/papers/7022716 | PubMed |
| 6,983,404 | Modulation of polyclonal B cell differentiation by human leucocyte alpha interferon. | Clin Exp Immunol | 1982 | https://conductscience.org/library/papers/6983404 | PubMed |
| 6,716,911 | Immunostimulation. Clinical and experimental perspectives. | Klin Wochenschr | 1984 | https://conductscience.org/library/papers/6716911 | PubMed |
| 6,444,662 | Interferon as a mediator of human lymphocyte suppression. | J Exp Med | 1980 | https://conductscience.org/library/papers/6444662 | PubMed |
| 6,409,809 | Recombinant mouse interferon-gamma regulation of antibody production. | Infect Immun | 1983 | https://conductscience.org/library/papers/6409809 | PubMed |
| 6,407,996 | Production of human interferon-gamma in serum-free medium. | Infect Immun | 1983 | https://conductscience.org/library/papers/6407996 | PubMed |
| 6,407,020 | Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. | Proc Natl Acad Sci U S A | 1983 | https://conductscience.org/library/papers/6407020 | PubMed |
| 6,317,573 | Production of gamma interferon in mice immune to Rickettsia tsutsugamushi. | Infect Immun | 1984 | https://conductscience.org/library/papers/6317573 | PubMed |
| 6,182,471 | Immunoregulation by gamma-interferon? | Nature | 1982 | https://conductscience.org/library/papers/6182471 | PubMed |
| 6,177,817 | Enhanced production of murine interferon gamma by T cells generated in response to bacterial infection. | J Exp Med | 1982 | https://conductscience.org/library/papers/6177817 | PubMed |
| 6,177,458 | Natural killer cell function in trisomy-21 (Down's syndrome). | Clin Exp Immunol | 1982 | https://conductscience.org/library/papers/6177458 | PubMed |
| 6,176,541 | Detection of gamma interferon in the sera of patients with Behçet's disease. | Infect Immun | 1982 | https://conductscience.org/library/papers/6176541 | PubMed |
| 6,167,846 | The interferon renaissance: molecular aspects of induction and action. | Microbiol Rev | 1981 | https://conductscience.org/library/papers/6167846 | PubMed |
| 6,157,362 | Type II interferon induction and passive transfer depress the murine cytochrome P-450 drug metabolism system. | Antimicrob Agents Chemother | 1980 | https://conductscience.org/library/papers/6157362 | PubMed |
| 6,156,452 | Mouse fibroblast (type I) and immune (type II) interferons: pronounced differences in affinity for gangliosides and in antiviral and antigrowth effects on mouse leukemia L-1210R cells. | Proc Natl Acad Sci U S A | 1980 | https://conductscience.org/library/papers/6156452 | PubMed |
| 6,155,926 | Enhancement of human natural cell-mediated cytotoxicity by interferon. | Br J Cancer | 1980 | https://conductscience.org/library/papers/6155926 | PubMed |
| 3,872,188 | Immunoregulatory effects of interferon-alpha. I. Interferon-alpha inhibits in vitro antibody synthesis by normal human lymphocytes. | Clin Exp Immunol | 1985 | https://conductscience.org/library/papers/3872188 | PubMed |
| 3,119,213 | Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset. | Cancer Immunol Immunother | 1987 | https://conductscience.org/library/papers/3119213 | PubMed |
| 2,936,412 | Abnormal expansions of granular lymphocytes: reactive lymphocytosis or chronic leukemia? Case report and literature review. | Blut | 1986 | https://conductscience.org/library/papers/2936412 | PubMed |
| 2,446,790 | Regulation of cell growth by interferon. | Cancer Metastasis Rev | 1987 | https://conductscience.org/library/papers/2446790 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/338162
GET https://conductscience.org/api/papers/v1/338162/cited_by?page=2